Vaxart Inc (VXRT) - Total Liabilities
Based on the latest financial reports, Vaxart Inc (VXRT) has total liabilities worth $85.94 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Vaxart Inc net asset momentum to track the company's year-over-year net asset growth rate.
Vaxart Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Vaxart Inc's total liabilities have evolved over time, based on quarterly financial data. See Vaxart Inc (VXRT) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Vaxart Inc Competitors by Total Liabilities
The table below lists competitors of Vaxart Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bastogi S.p.A
F:BAOA
|
Germany | €190.94 Million |
|
Clal Industries and Beverages Ltd
TA:CLBV
|
Israel | ILA309.55 Million |
|
Horizon Copper Corp.
V:HCU
|
Canada | CA$610.65 Million |
|
Tecogen Inc.
NYSE:TGEN
|
USA | $15.52 Million |
|
Sangoma Technologies Corp
TO:STC
|
Canada | CA$116.38 Million |
|
BlackRock Long-Term Municipal Advantage Trust
NYSE:BTA
|
USA | $83.96 Million |
|
DSC Investment Inc
KQ:241520
|
Korea | ₩43.38 Billion |
|
Chunil Express
KO:000650
|
Korea | ₩42.56 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Vaxart Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VXRT stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaxart Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaxart Inc (1985–2025)
The table below shows the annual total liabilities of Vaxart Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $98.28 Million | -8.55% |
| 2024-12-31 | $107.46 Million | +215.84% |
| 2023-12-31 | $34.02 Million | -21.33% |
| 2022-12-31 | $43.25 Million | +28.58% |
| 2021-12-31 | $33.64 Million | +15.28% |
| 2020-12-31 | $29.18 Million | +21.17% |
| 2019-12-31 | $24.08 Million | +0.38% |
| 2018-12-31 | $23.99 Million | +12.10% |
| 2017-12-31 | $21.40 Million | -19.25% |
| 2016-12-31 | $26.50 Million | +167.68% |
| 2015-12-31 | $9.90 Million | -63.47% |
| 2014-12-31 | $27.10 Million | +52.25% |
| 2013-12-31 | $17.80 Million | +10.56% |
| 2012-12-31 | $16.10 Million | -58.82% |
| 2011-12-31 | $39.09 Million | -26.65% |
| 2010-12-31 | $53.30 Million | +57.18% |
| 2009-12-31 | $33.91 Million | +48.47% |
| 2008-12-31 | $22.84 Million | -75.19% |
| 2007-12-31 | $92.04 Million | -40.42% |
| 2006-12-31 | $154.49 Million | -7.77% |
| 2005-12-31 | $167.51 Million | +99.77% |
| 2004-12-31 | $83.85 Million | +23.34% |
| 2003-12-31 | $67.98 Million | +55.26% |
| 2002-12-31 | $43.79 Million | -64.43% |
| 2001-12-31 | $123.10 Million | -16.31% |
| 2000-12-31 | $147.09 Million | -5.95% |
| 1999-12-31 | $156.40 Million | -4.69% |
| 1998-12-31 | $164.10 Million | +9.25% |
| 1997-12-31 | $150.20 Million | +29.48% |
| 1996-12-31 | $116.00 Million | +69.10% |
| 1995-12-31 | $68.60 Million | +63.33% |
| 1994-12-31 | $42.00 Million | +20.34% |
| 1993-12-31 | $34.90 Million | +3.87% |
| 1992-12-31 | $33.60 Million | +192.17% |
| 1991-12-31 | $11.50 Million | -0.86% |
| 1990-12-31 | $11.60 Million | -21.09% |
| 1989-12-31 | $14.70 Million | +16.67% |
| 1988-12-31 | $12.60 Million | +125.00% |
| 1987-12-31 | $5.60 Million | -23.29% |
| 1986-12-31 | $7.30 Million | 0.00% |
| 1985-12-31 | $7.30 Million | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phas… Read more